{"organizations": [], "uuid": "ca57180bfcb2171e0319e08649a065fc93f93156", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-eli-lilly-says-new-data-show-truli/brief-eli-lilly-says-new-data-show-trulicity-combo-treatment-improves-blood-sugar-control-in-type-2-diabetes-patients-idUSFWN1QG0O7", "country": "US", "domain_rank": 408, "title": "BRIEF-Eli Lilly Says New Data Show Trulicity Combo Treatment Improves Blood Sugar Control In Type 2 Diabetes Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.251, "site_type": "news", "published": "2018-02-26T20:12:00.000+02:00", "replies_count": 0, "uuid": "ca57180bfcb2171e0319e08649a065fc93f93156"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eli-lilly-says-new-data-show-truli/brief-eli-lilly-says-new-data-show-trulicity-combo-treatment-improves-blood-sugar-control-in-type-2-diabetes-patients-idUSFWN1QG0O7", "ord_in_thread": 0, "title": "BRIEF-Eli Lilly Says New Data Show Trulicity Combo Treatment Improves Blood Sugar Control In Type 2 Diabetes Patients", "locations": [], "entities": {"persons": [{"name": "lilly", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "eli lilly and co", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "brief-eli lilly says new data", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Eli Lilly And Co:\n* ELI LILLY SAYS NEW DATA SHOW TRULICITY (DULAGLUTIDE) IN COMBINATION WITH SGLT-2 INHIBITOR IMPROVES BLOOD SUGAR CONTROL IN PEOPLE WITH TYPE 2 DIABETES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T20:12:00.000+02:00", "crawled": "2018-02-27T15:21:18.003+02:00", "highlightTitle": ""}